Recurrent Neoatherosclerosis After Bioresorbable Vascular Scaffold Treatment of In-Stent Restenosis.
نویسندگان
چکیده
A 66-year-old manpresentedanon–ST-segment elevation myocardial infarction 3 years after the implantation of an everolimuseluting stent (3.5 12 mm) in the proximal segment of a saphenous vein graft to a marginal branch. Coronary angiography showed focal in-stent restenosis (ISR) and optical coherence tomography (OCT) confirmed severe ISR (minimal lumen area 3.1 mm). Notably, the tissue causing ISR had a striking
منابع مشابه
Bioresorbable vascular scaffold: promises and the fallen child-as-king?
Correspondence to Stéphane Cook; [email protected] THE BIORESORBABLE VASCULAR SCAFFOLDS ‘BVS’ The main limitation of percutaneous coronary intervention compared to open-heart surgery is the insertion of a foreign body (usually a stent) inside the coronary artery. This is associated with foreign body inflammation that triggers restenosis, neoatherosclerosis and late-occurring stent thrombos...
متن کاملClinical Outcomes From The Bioresorbable Vascular Scaffold: Is There A Role for Them?
The risk of stent thrombosis and restenosis with the second generation drug eluting stents remains. The bioresorbable vascular scaffold is a third generation stent and overcomes the problems associated with drug eluting metallic stents. The bioresorbable vascular scaffold completely absorbs within the coronary vessel over 3-5 years. Multiple trials in patients with non complex coronary disease ...
متن کاملLong-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis
Treatment of in-stent restenosis (ISR) is still a technical challenge for interventional cardiologists. Several studies have demonstrated that treating drug-eluting stent (DES) ISR is even more challenging because of the unfavorable substrate of DES ISR because of the presence of resistant stent underexpansion or neoatherosclerosis that have been shown to be associated with poorer clinical and ...
متن کاملThe first generation ABSORB BVS scaffold; to be or not to be?
In the routine treatment of coronary artery disease, balloon angioplasty has been replaced by stents. The use of bare-metal stents resulted in lower rates of restenosis and repeat revascularisations. Drug-eluting stents (DES), designed with thinner struts and anti-proliferative drugs, have further enhanced the efficacy and safety of percutaneous coronary intervention. Nevertheless, the new gene...
متن کاملBioresorbable Vascular Scaffolds for Coronary Revascularization.
Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction, restenosis) after 1 year. The pathogenesis of these very late events is likely related to the permanent presence of the metal stent frame or polymer. Bioresorbable scaffolds have been developed to provide drug delivery an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- JACC. Cardiovascular interventions
دوره 8 9 شماره
صفحات -
تاریخ انتشار 2015